Redefining Systemic Sclerosis Classification: Anti-Topoisomerase Antibody as a Superior Predictor of Interstitial Lung Disease and Skin Progression Compared to Limited Cutaneous Systemic Sclerosis Subset

<b>Background:</b> Currently, no information exists on the clinical course of anti-topoisomerase I antibody (ATA)-positive limited cutaneous systemic sclerosis (lcSSc). We aimed to evaluate the incidence of and time to the development of interstitial lung disease (ILD), pulmonary hypertension (PHT),...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Chana Chaovanitkul, Tippawan Onchan, Patnarin Pongkulkiat, Ajanee Mahakkanukrauh, Siraphop Suwannaroj, Chingching Foocharoen
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	MDPI AG 2025-07-01
Cyfres:	Life
Pynciau:	systemic sclerosis scleroderma and related disorders antigens and autoantibodies observational studies skin respiratory
Mynediad Ar-lein:	https://www.mdpi.com/2075-1729/15/7/1067
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!